Unicycive Therapeutics, Inc. (UNCY): Total Liabilities
$18.94M
As of 2025-12-31
$18.76M
As of 2026-06-30
+79.3%
3-year compound annual growth
+45.8%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $18.94M | -21.9% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $24.24M | +34.7% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $18.00M | +448.1% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $3.28M | +45.3% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $2.26M | -21.4% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $2.88M | n/a | 2022-03-31, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Unicycive Therapeutics, Inc. (UNCY) | 2025-12-31 | $18.94M | -21.9% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $13.04M | -6.5% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $6.92M | +45.1% |
| NextCure, Inc. (NXTC) | 2025-12-31 | $15.24M | -1.0% |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | $34.90M | +208.9% |
| Akari Therapeutics Plc (AKTX) | 2025-12-31 | $19.56M | -30.9% |
| Atossa Therapeutics, Inc. (ATOS) | 2025-12-31 | $8.26M | +66.2% |
| Verrica Pharmaceuticals Inc. (VRCA) | 2025-12-31 | $22.39M | -65.0% |
| Actinium Pharmaceuticals, Inc. (ATNM) | 2025-12-31 | $43.94M | -0.5% |
Compare UNCY, VTGN, COYA, NXTC side by side · Screen every company in Pharmaceutical Preparations ↗